NCT05567887

Simple Title
A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TTI-622 (PF-07901801), A SINGLE AGENT IN JAPANESE PARTICIPANTS WITH RELAPSED OR REFRACTORY LYMPHOMA

Lymphoma

Who may participate

Each clinical study has its own guidelines for who may participate, called eligibility criteria. These factors can include your age, sex, overall health, type and stage of disease, and personal treatment history. However, only the research study staff can determine if you qualify to enroll in the study.

Condition

Lymphoma

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
Sex
Male or Female
The sex of people who may participate in a clinical trial (all, female, male). Sex is a person’s classification based on assignment at birth. Eligibility based on sex is distinct from eligibility based on gender.
Age
18+ years
The age a person must be to participate in a clinical trial.
View more eligibility criteria on ClinicalTrials.gov

Study Locations

Study Locations
2 trials found.

Japanese Foundation for Cancer Research

Koto, Tokyo, Japan, 135-8550
Recruiting Get directions

Yamagata University Hospital

Yamagata, Japan, 990-9585
Recruiting Get directions